nucleos(t)ide

Phase 1Small molecule

Roche

nucleos(t)ide is one of 52 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatitis BActive, not recruiting

Chronic HepatitisPhase 1

Active, not recruiting

Hepatitis BPreclinical

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

SOF/VEL

Gilead

Preclinical

4 9

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

1 10

Peg-IFN Alfa-2b

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Recruiting

Hepatitis B

NCT04896255

Clinical

Trials by Indication[1]

Chronic Hepatitis2 trials

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Completed·AAssembly Biosciences·Phase 1·NCT02908191·86 enrolled

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Completed· Roche logo

Roche·Phase 2·NCT04225715·281 enrolled

Hepatitis B1 trial

Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B

Recruiting·HHuashan Hospital··NCT04896255·33,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for nucleos(t)ide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nucleos(t)ide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nucleos(t)ide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

nucleos(t)ide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Chronic Hepatitis2 trials

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News